$VIVE News

Last published 4y ago

4y agoVIVEViveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceACCESS NewswirePatent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused
4y agoVIVEViveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial ReadoutACCESS NewswireNew branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in Women Completion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results expected shortly thereafter ENGLEWOOD, CO / ACCE
4y agoVIVEViveve to Participate in Ladenburg Thalmann Healthcare ConferenceACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive office
4y agoVIVEViveve to Participate in Alliance Global Partners Virtual MedTech ConferenceACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive office
4y agoVIVEViveve to Participate in H.C. Wainwright 24th Annual Global Investment ConferenceACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer
4y agoVIVEViveve Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateACCESS NewswireTotal revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / Au
4y agoVIVEViveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022ACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 fi
4y agoVIVEViveve to Participate in H.C. Wainwright Global Investment ConferenceACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment
4y agoVIVEViveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology ReportACCESS NewswireDurbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical techn
4y agoVIVEViveve Reports First Quarter 2022 Financial Results and Provides Corporate UpdateACCESS NewswireTotal revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / May 12, 2022 / Viv
4y agoVIVEViveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022ACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update
4y agoVIVEViveve Reports Full Year 2021 Financial Results and Provides Corporate UpdateACCESS NewswireReported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underway PURSUIT top-line re
4y agoVIVEViveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022ACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 financial results and provide a corporate update afte
4y agoVIVEHealthcare Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical DevicesACCESS NewswireViveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / January 13, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical
4y agoVIVEViveve to Participate in H.C. Wainwright BIOCONNECT ConferenceACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright BIOCONNECT Conf
4y agoVIVEViveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary IncontinenceACCESS NewswireMajor milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it
5y agoVIVEViveve Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateACCESS NewswireTotal revenue of $1.6M reported for Q3 Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology comp
5y agoVIVEViveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate UpdateACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate upda
5y agoVIVEViveve Announces Issuance of New Device and Methods Patent in U.SACCESS NewswireIssuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that
5y agoVIVEViveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in AustraliaACCESS NewswirePatent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women'
5y agoVIVEViveve to Participate in H.C. Wainwright 23rd Annual Global Investment ConferenceACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 23rd
5y agoVIVEViveve Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateACCESS NewswireTotal revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for completion in early Q4 Potential long-term reimbursemen
5y agoVIVEViveve to Host Conference Call on August 12, 2021 to Report Second Quarter Financial Results and Provide Corporate UpdateACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / August 5, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter 2021 financial results and provide a corporate updat
5y agoVIVEViveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian PatentACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Canadian Intellectual Property Office (CIPO) recently issued Canadian Patent No. 3
5y agoVIVEViveve Announces New Category III CPT Code for its Stress Urinary Incontinence ProcedureACCESS NewswireNew code approved by American Medical Association and supported by key medical societies Long-term pathway for potential reimbursement now established for Company's dual-energy noninvasive treatment for urethral hypermobility to improve stress urinary i
5y agoVIVEViveve to Participate in Ladenburg Thalmann Healthcare Virtual ConferenceACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / July 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Health
5y agoVIVEViveve Announces Issuance of New Device and Methods Patent in U.S.ACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 1
5y agoVIVEViveve Announces Adjournment of Annual MeetingACCESS NewswireMeeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time Company encourages stockholders to cast their votes ENGLEWOOD, CO / ACCESSWIRE / June 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's
5y agoVIVEViveve Reports First Quarter 2021 Financial Results and Provides Corporate UpdateACCESS NewswirePivotal SUI PURSUIT trial enrollment underway and accelerating Total revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portfolio in key Asia Pacific markets ENGLEWOOD, CO / ACCESSWIRE / May 13, 2021 / Vivev
5y agoVIVEViveve Medical, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 13, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 5:00 PM Eastern Time. To listen to the event live or access a
5y agoVIVEViveve Announces Adjournment of Annual MeetingACCESS NewswireMeeting scheduled to reconvene June 2, 2021 at 12:00 PM Eastern Time Company encourages stockholders to cast their votes ENGLEWOOD, CO / ACCESSWIRE / May 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's i
5y agoVIVEViveve To Host Conference Call on May 13, 2021 To Report First Quarter Financial Results and Provide Corporate UpdateACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / May 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2021 financial results and provide a corporate update af
5y agoVIVEViveve Announces Expansion of IP Portfolio with Patent Issuance in TaiwanACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for Viveve's dual-energy technology device. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one o ...
5y agoVIVEViveve Reports Full Year 2020 Financial Results and Provides Corporate UpdateACCESS NewswireCompany continuing to advance its U.S. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET today
5y agoVIVEViveve to Participate in the H.C. Wainwright Global Life Sciences Virtual ConferenceACCESS NewswireViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the virtual H.C. Wainwright Global Life Sciences Conference, March 9 - 10, 2021. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the conference. Due to the cor ...
5y agoVIVEViveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020ACCESS NewswireViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced topline financial results for the quarter ended December 31, 2020. Based on fourth-quarter 2020 estimated total revenue of $1.9 million, a continued reduction in operating expenses, and a strengthened cash position following the close of the Company's recent upsized financing of $27 ...
5y agoVIVEViveve Recognized for Leadership in Appointing Women to Board of DirectorsACCESS NewswireColorado Women on Boards Coalition names Viveve as top Colorado public company
5y agoVIVEViveve Announces Expansion of IP Portfolio with Issuance of S. Korean PatentACCESS NewswireViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Korean Intellectual Property Office (KIPO) recently issued Korean Patent No. 10-2197234 titled, Vaginal Remodeling Device and Method. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's largest commercial markets.
5y agoVIVEViveve Regulatory Executive Named Among Top 25 Women Leaders in Medical DevicesACCESS NewswireHealthcare Technology Report award recognizes outstanding contributions by SVP Suzon Lommel to advance innovative technologies that can transform patient outcomes
5y agoVIVEProspective US Radiofrequency SUI Trial - NCT04720352ClinicalTrials.gov1-hour pad weight test, 3-day diary, Patient Global Impression of Improvement (PGI-I), (and 3 more...)
5y agoVIVEViveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary IncontinenceACCESS NewswireViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it has initiated its multicenter, randomized, double-blinded, sham-controlled trial entitled Prospective U.S. Radiofrequency SUI Trial (PURSUIT). The protocol of the PURSUIT Trial reflects changes to the study design that were approved by the U.S. Food and Drug Administration ( ...
5y agoVIVEViveve Announces Closing of an Upsized $27.6 Million Underwritten Public Offering and Exercise of Over-Allotment OptionACCESS NewswireViveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $27.6 million, which includes the exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts ...
5y agoVIVEViveve Announces Pricing of Upsized $24 Million Underwritten Public OfferingACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / January 14, 2021 / Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the pricing of an upsized underwritten public offering of units for gross proceeds of approximately $24 Million (or $27.6 million if the underwriters exercise their option to purchase additional shares) prior to deducting un ...
5y agoVIVEViveve Regains Compliance with NASDAQ Continued Listing RulesACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / December 17, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on December 16, 2020 that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2) for continued lis ...
5y agoVIVEViveve Announces FDA Approval of Proposed Amendments to Pivotal U.S. PURSUIT Trial ProtocolACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that the Company's proposed changes to the study design of its pivotal PURSUIT trial were approved by the U.S. Food and Drug Administration (FDA.) The Company submitted certain protocol amendments to the FDA in October intended to str ...
5y agoVIVEViveve Announces FDA 510K Approval to Expand Manufacturing of Treatment TipsACCESS NewswireApproval strengthens supply chain and reduces manufacturing costs for consumable component used with Viveve's Cryogen-cooled Monopolar Radiofrequency technology
6y agoVIVEViveve Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateACCESS NewswireViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2020, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.
6y agoVIVEViveve to Participate in Alliance Group Partners Virtual Healthcare SymposiumACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / November 10, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Alliance Group Partners Virtual Healthcare Symposium on November 19, 2020. Mr. Durbin will meet with members of the investment community in virtual one-on-one meeting ...
6y agoVIVEViveve to Host Conference Call on November 12, 2020 to Report Third Quarter Financial Results and Provide Corporate UpdateACCESS NewswireENGLEWOOD, CO / ACCESSWIRE / November 5, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2020 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 12, 2020. The Company will host a conference call and webcast at 5:00 PM ET ...
6y agoVIVEViveve Appoints New Independent Board DirectorACCESS NewswireViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Sharon Collins Presnell, Ph.D. has joined the Viveve board of directors and its audit committee, effective October 28, 2020. The appointment of Dr. Presnell brings the company in compliance with the corporate governance requirements under Listing Rules 5605(b)(1) and 5605(c)(2) ...